Skip to NavigationSkip to content

Beverley Carr appointed Chief Business Officer for Amphista Therapeutics

Published on: 02/11/21

Amphista Therapeutics have appointed Beverley Carr Chief Business Officer. Amphista is a leader in next generation targeted protein degradation (TPD) approaches.

Beverley Carr commented: “I’m delighted to join Amphista’s world-class team. Amphista is founded on transformational science and I’m looking forward to driving the Company’s business development strategy as we execute our mission of building the leading TPD company.”

Amphista’s CEO Dr Nicola Thompson said: “On behalf of the Amphista team, I am thrilled to welcome Beverley as our CBO. Beverley brings a wealth of business development expertise from an impressive career as a business leader, spanning both Pharma and Biotech.”

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches